On February 21, 2013, Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional, S.A. announced that the European Commission has granted marketing authorization for ADASUVEŽ (StaccatoŽ loxapine). The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

(d) Exhibits.

Exhibit Number         Description

99.1                   Press Release titled "Alexza Receives Marketing
                       Authorization for ADASUVEŽ (StaccatoŽ Loxapine) in the
                       European Union," dated February 21, 2013.